A case of myopericarditis following administration of the Pfizer COVID-19 vaccine
##plugins.themes.bootstrap3.article.main##
##plugins.themes.bootstrap3.article.sidebar##
http://orcid.org/0000-0002-8188-7373
Danetta Green
http://orcid.org/0000-0001-5046-5365
Matt Grisham
http://orcid.org/0000-0002-3417-6421
Abstract
Numerous vaccines have been developed to address the COVID-19 pandemic, the most frequently administered are the Moderna and Pfizer-BioNTech (Pfizer) mRNA COVID-19 vaccines. Of 177 million individuals that have full vaccination status, there have been 1,148 cases of myocarditis or pericarditis reported. At this time, the relationship between myopericarditis and the Pfizer mRNA COVID-19 vaccine has not been well established in current literature due to the novelty of the vaccine. We discuss a 16-year-old male who presented to the emergency department with chest pain 48 hours after receiving his second dose of the Pfizer COVID-19 vaccine. His laboratory and electrocardiogram findings were consistent with acute myopericarditis and work-up did not reveal an obvious etiology. After starting anti-inflammatory therapies, the patients symptoms and laboratory markers improved and the patient was discharged from the hospital expected to make a full recovery. This case demonstrates the rapid recovery with no sequelae following this adverse effect, highlighting that the benefits of the COVID-19 vaccination most likely outweigh the risks.
##plugins.themes.bootstrap3.article.details##
COVID-19 vaccine, myopericarditis, pediatric, adverse effect
2. Centers for Disease Control and Prevention. Understanding How COVID-19 Vaccines Work. [https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/how-they-work.html available at 01.11.2022]
3. Centers for Disease Control and Prevention. Selected Adverse Events Reported after COVID-19 Vaccination. [https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/adverse-events.html available at 01.11.2022]
4. Gargano JW, Wallace M, Hadler SC, et al. Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: Update from the Advisory Committee on Immunization Practices—United States. MMWR Morb Mortal Wkly Rep. 2021; 70(27):977-982. http://dx.doi.org/10.15585/mmwr.mm7027e2
5. Salah HM, Mehta JL. COVID-19 vaccine and myocarditis. Am J Cardiol. 2021; 157:146-148. https://doi.org/10.1016/j.amjcard.2021.07.009
6. Bozkurt B, Kamat I, Hotez PJ. Myocarditis with COVID-19 mRNA vaccines. Circulation. 2021; 144(6):471-484. https://doi.org/10.1161/CIRCULATIONAHA.121.056135
7. Vojdani A, Kharrazian D. Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases. Clin Immunol. 2020; 217:108480. https://doi.org/10.1016/j.clim.2020.108480
8. U.S. Department of Health and Human Services. Vaccine Adverse Event Reporting System. [https://vaers.hhs.gov/ available at 01.11.2022]
Archive of Clinical Cases is protected by copyright and may be used in accordance with copyright and other applicable laws. Content available at www.clinicalcases.eu and our digital applications is intended for personal noncommercial use.
Authors who submit a manuscript for publication in Archive of Clinical Cases agree to the following terms: a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) only after the final version of the manuscript was accepted and published, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access). d. It is compulsory that before submission authors ensure that their work was not published in any other medical journals or pending acceptance for publication and that "Archives of Clinical Cases" is the only beneficiary at that moment if their work/case will be accepted by us.
Guidelines for linking to www.clinicalcases.eu a. The main purpose of the site linking to the Archive of Clinical Casess site should be educational. b. Links should be made to the Archive of Clinical Casess home page (www.clinicalcases.eu) or to the articles abstract. c. It is forbidden to use the Archive of Clinical Casess cover by outside organizations unless permission has been granted in advance, notifying our Secretary. d. Material owned by the Archive of Clinical Cases (including the name, logo, cover, and text) may not be used in any manner that may induce the idea or suggest that the Archive of Clinical Cases is in some way recommending a specific company, product or service. e. You must not use or allow others to access or use, all or any part of our Site or the contents and/or applications on it for commercial purposes without our permission. To seek permission to do anything prohibited by or not contained in these TERMS, or which requires our prior consent or agreement, you can contact us.